Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma

HER2+/ER+ breast cancer, a subset of the luminal B subtype, makes up approximately 10% of all breast cancers. The bidirectional crosstalk between HER2 and estrogen receptor (ER) in HER2+/ER+ breast cancer contributes to resistance towards both anti-estrogens and HER2-targeted therapies. TFF3 promote...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Chong, Qing-Yun, You, Ming-Liang, Pandey, Vijay, Banerjee, Arindam, Chen, Yi-Jun, Poh, Han-Ming, Zhang, Mengyi, Ma, Lan, Zhu, Tao, Basappa, Salundi, Liu, Liang, Lobie, Peter E.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5650333/
https://ncbi.nlm.nih.gov/pubmed/29088778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18431
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars